Answers are grounded in this paper and cite their sources.
Background Enterococci are a frequent cause of urinary tract infection (UTI) in community and hospital settings, and resistance to fluoroquinolones is increasing. Efflux pumps contribute to this resistance, so efflux pump inhibitors (EPIs) may help restore fluoroquinolone activity. Objectives To determine the prevalence of the efflux pump genes emeA, efrA and efrB in uropathogenic Enterococcus isolates, to relate them to fluoroquinolone resistance, and to measure how verapamil and chlorpromazine change ciprofloxacin and levofloxacin minimum inhibitory concentrations (MICs). Methods Fifty-three Enterococcus isolates from urine, collected at the Department of Microbiology and Immunology, Bangladesh Medical University (BMU), Dhaka, between March 2023 and February 2024, were identified by biochemical tests. Fluoroquinolone susceptibility was tested with VITEK® 2 Compact. The genes emeA, efrA and efrB were detected by conventional PCR. Ciprofloxacin and levofloxacin MICs were determined by broth microdilution, with and without verapamil (100 µg/mL) or chlorpromazine (20 µg/mL), in resistant isolates carrying efflux pump genes. A reduction in MIC of at least four-fold was defined as effective. Results E. faecalis (43/53, 81.1%) and E. faecium (5/53, 9.4%) predominated. Resistance to ciprofloxacin was 66.0% (35/53) and to levofloxacin 62.3% (33/53). emeA was more frequent in resistant than in non-resistant isolates (ciprofloxacin 80.0% vs 22.2%; levofloxacin 78.8% vs 25.0%; both p < 0.001), as was efrAB (51.4% vs 11.1%, p = 0.006; 51.5% vs 10.0%, p = 0.003). Among 29 ciprofloxacin-resistant isolates, an effective MIC reduction occurred in 16 (55.2%) with verapamil and 23 (79.3%) with chlorpromazine. Among 26 levofloxacin-resistant isolates, it occurred in 19 (73.1%) with verapamil and 17 (65.4%) with chlorpromazine. Chlorpromazine lowered the ciprofloxacin MIC50/MIC90 from 16/32 to 4/8 µg/mL; verapamil and chlorpromazine lowered the levofloxacin MIC50/MIC90 from 16/32 to 2/8 and 4/8 µg/mL, respectively. Conclusion Verapamil and chlorpromazine both reduced fluoroquinolone MICs in efflux gene-positive, fluoroquinolone-resistant enterococci. Chlorpromazine was more effective for ciprofloxacin, and the two inhibitors were comparable for levofloxacin. These in vitro findings justify further work on safer EPIs and on the role of efflux in enterococcal fluoroquinolone resistance.
No takes yet. Share an insight, caveat, or question.
Alam et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: